Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Cardiologists identify blood protein fragment that can predict heart attack

Cardiologists at the University of Connecticut Health Center have identified a protein fragment that when detected in the blood can be a predictor of heart attack.

6 Jan 2011

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.

6 Jan 2011

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Cell Biosciences, a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem M MultiFluor system.

5 Jan 2011

First whole genome sequence of Parsi breast cancer woman

Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.

4 Jan 2011

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Clinical Data, Inc. today announced that the Company has closed the sale of its genetic and pharmacogenomic testing and biomarker development business to Transgenomic, Inc. for $15.5 million. The sale completes Clinical Data's transformation into a pharmaceutical company with a deep product pipeline, including two promising late-stage compounds, the most advanced of which is vilazodone, a new treatment in development for Major Depressive Disorder.

30 Dec 2010

Researchers develop breath-analysis technology for rapid detection of biomarkers

Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

29 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Exiqon A/S, a leading provider of technologies for biomarker detection, today announced the introduction of GLP compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.

27 Dec 2010

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family, "RS7 antibodies," were issued as Patent No. 1,002,443 in Korea.

23 Dec 2010

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

A study in this week's PLoS Medicine suggests that AIDS patients with cryptococcal meningitis who start HIV therapy are predisposed to immune reconstitution inflammatory syndrome - an exaggerated inflammatory immune response that kills up to one-third of affected people - if they have biomarkers in their blood showing evidence of a damaged immune system that is not capable of clearing the fungal infection.

22 Dec 2010

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Exiqon A/S today announced the completion of the discovery phase in its program for early detection of colorectal cancer in blood.

21 Dec 2010

Study reveals novel role of adenosine signaling in sickle cell disease

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Novel Role of Adenosine Signaling in Sickle Cell Disease", in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.

21 Dec 2010

HistoRx grants Metamark worldwide license to AQUA technology for commercialization of Prognostic Assays

Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, today announced a multi-year licensing agreement. HistoRx has granted Metamark a worldwide license to the AQUA technology for the clinical commercialization of Metamark's proprietary MetamarkDx™ Prognostic Assays.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

Genetic biomarker linked to increased risk for breast cancer found in 'junk' DNA

A new genetic biomarker that indicates an increased risk for developing breast cancer can be found in an individual's "junk" (non-coding) DNA, according to a new study featuring work from researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and their colleagues.

17 Dec 2010

Biomarker News and Research

Further Reading

Mutated TDP-43 can cause neurons to die: Study

Scientists identify prognostic biomarker to treat patients with HCV

Cardiologists identify blood protein fragment that can predict heart attack

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

First whole genome sequence of Parsi breast cancer woman

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Researchers develop breath-analysis technology for rapid detection of biomarkers

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Immunomedics announces additional claim for RS7 antibodies patent family

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Study reveals novel role of adenosine signaling in sickle cell disease

HistoRx grants Metamark worldwide license to AQUA technology for commercialization of Prognostic Assays

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

Genetic biomarker linked to increased risk for breast cancer found in 'junk' DNA

eBook: Cellular Senescence eBook

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest Life Science News